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Abstract: Neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision has emerged
as the standard treatment for locally advanced rectal cancer (LARC) patients. However, many
cases do not respond to neoadjuvant CRT, suffering unnecessary toxicities and surgery delays.
Thus, identification of predictive biomarkers for neoadjuvant CRT is a current clinical need. In the
present study, microRNA-31 expression was measured in formalin-fixed paraffin-embedded (FFPE)
biopsies from 78 patients diagnosed with LARC who were treated with neoadjuvant CRT. Then, the
obtained results were correlated with clinical and pathological characteristics and outcome. High
microRNA-31 (miR-31) levels were found overexpressed in 34.2% of cases. Its overexpression
significantly predicted poor pathological response (p = 0.018) and worse overall survival (OS)
(p = 0.008). The odds ratio for no pathological response among patients with miR-31 overexpression
was 0.18 (Confidence Interval = 0.06 to 0.57; p = 0.003). Multivariate analysis corroborated the clinical
impact of miR-31 in determining pathological response to neoadjuvant CRT as well as OS. Altogether,
miR-31 quantification emerges as a novel valuable clinical tool to predict both pathological response
and outcome in LARC patients.
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1. Introduction
Colorectal carcinoma (CRC) incidence, morbidity, and mortality rates vary markedly around
the world, and rectal carcinoma represents approximately 28% of all CRC [1]. The standard of
care for locally advanced rectal cancer (LARC) involves a multidisciplinary approach consisting of
neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision (TME) surgery. This fact
was established after several studies showing that CRT before total mesorectal excision (neoadjuvant
chemoradiotherapy) was associated with a lower percentage of patients with local recurrence than
either with total mesorectal excision surgery followed by adjuvant CRT or total mesorectal excision
surgery alone [2,3]. After the initiation of neoadjuvant CRT, a relevant observation is the range of
pathological tumor response, from cases achieving a pathological complete response (pCR; ypT0N0)
to others getting an absence of tumor regression at all or even tumor progression during therapy [4,5].
Of importance, pCR detected by pathological examination of the resected specimen is associated
with significantly better prognosis as compared with patients with residual tumor, particularly
residual nodal disease. Similarly, minimal residual disease is associated with better prognosis than
gross residual disease [6,7]. Currently, the neoadjuvant CRT regimen most widely used is based
on fluoropyrimidines concurrent with conventional fractionation radiotherapy [2]. Nevertheless,
more than one-third of cases develop distant metastasis within 10 years from diagnosis and complete
pathological response only occurs in 8% to 14% of patients. Thus, those patients who do not respond
suffer undesired toxicities and delays in the resection of the primary tumor [8,9].
There are currently no effective methods to predict which patients will respond to neoadjuvant
CRT. Despite some prognostic factors of local recurrence, distant recurrence and outcome have been
proposed after tumor mesorectal excision surgery [10–12]; neoadjuvant CRT predictive biomarkers
with an impact in recurrence and outcome are not still established in clinical practice [12–14].
The identification of patients who have a higher possibility of responding to preoperative CRT could
be important in improving survival and decreasing treatment morbidity and local control in LARC.
Moreover, patients who are potential non-responders could be moved to alternative therapeutic
strategies. Therefore, the identification of novel alterations with predictive value of response to
neoadjuvant CRT would be of high relevance for an optimal multidisciplinary treatment approach in
this LARC patient subgroup.
MicroRNAs (miRNAs) are short (18–27 nucleotides) non-coding single-stranded RNA molecules
which negatively regulate the expression of specific target genes at the post-transcriptional level.
Depending on their target genes, microRNA deregulation has been related to CRC development,
progression, or therapy response. Moreover, they can be easily detected in rectal cancer tissue and
blood, so they have been proposed as promising biomarkers for diagnosis, prognosis, and monitoring
therapies in this disease [15–17]. MicroRNA-31 (miR-31) maps on 9p21.3 and is one of the most
significantly deregulated miRNAs in rectal cancer. It has been reported to be overexpressed in CRC
cell lines as well as in rectal tumor tissue compared with the normal paired rectal mucosa [18].
In functional studies, the inhibition of miR-31 is able to impair CRC cell proliferation, invasion,
and promote apoptosis—which suggests its oncogenic role in this disease [19]. Furthermore, high
miR-31 levels have been described to correlate with tumor stage [18,20], poor prognosis [21], and
shorter progression-free survival in CRC patients treated with anti-epithelial growth factor receptor
(anti-EGFR) therapies [21]. Of importance, miR-31 suppression increases sensitivity to 5-fluorouracil
(5-FU) and affects cell migration and invasion in the CRC cell line HCT-116 [22]. However, miR-31
ability to predict neoadjuvant CRT pathological response and outcome in LARC is a relevant question
that remains to be explored. Here, we report that miR-31 deregulation is a common event in LARC
that determines poor outcome. Moreover, this alteration is of high therapeutic relevance because it
defines a subgroup of LARC patients who will not respond to neoadjuvant CRT.
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2. Results
2.1. Prevalence of miR-31 Deregulation in Locally Advanced Rectal Cancer (LARC) and Its Relation with
Pathological and Clinical Characteristics
Eighty-two patients with LARC treated with neoadjuvant CRT were selected. All of them had
a minimal follow-up greater than three years. The cohort flowchart diagram is shown in Figure 1.
Owing to the loss of clinical follow-up data, four patients were excluded. Complete response, moderate
response, minimal response, and a poor response was observed in 12.3%, 37%, 18.3%, and 28.4% of
patients, respectively.
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Clinical and pathological characteristics nº Cases 
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nº miR-31 
Low 2 (%) p 
miR-31 3 pre CRT 78 (100%) 27 (34.2) 51 (65.8) 
0.267 
Age 
<60 24 (30.7) 10 (41.6) 14 (58,4) 
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Male 47 (60) 15 (31.9) 32 (68.1) 
0.454 Female 31 (40) 8 (68.1) 19 (31.9) 
ECOG 4 
0 49 (62.8) 14 (28.5) 35 (71.5) 
0.113 I 29 (37.2) 13 (71.5) 16 (28.5) 
Clinical stage pre CRT 5 
II 4 (5.2) 3 (75) 1 (25) 
0.121 III 73 (94.8) 24 (30.7) 49 (69.3) 
Neoadjuvant CRT RT + 5-FU 6 based 78 (100%)    
Adjuvant therapy 
5-FU 55 (70.5) 20 (36.4) 35 (63.6) 
0.407 FOLFOX 7 6 (7.7) 3 (50) 3 (50) 
Other 17 (21.8) 4 (23.5) 13 (76.5) 
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Figure 1. Patients flowchart through the study. CRT: chemoradiotherapy.
High miR-31 levels were observed in 34.2% of cases (27 out of 78). To explo the potential value
of miR-31 predicting response to neoadjuvant CRT, patients with different grades of pathological
response were compared. Interestingly, those patients who developed complete response tended to
have low microRNA-31 levels, whereas the subgroup of patients with a poor pathological response
showed high levels of miR-31. (p = 0.018). No statistical significance was observed in age, sex, Eastern
Cooperative Oncology Group (ECOG) scale of perf rmance status, histological grade, clinical stage,
tumor size, and lymph node stage between patients with high and low miR-31 expression levels
(Table 1). Similarly, no differences were found for pathological stage and downstaging.
Table 1. Baseline clinical and pathological characteristics of our locally advanced rectal cancer (LARC)
cohort and its relation with miR-31 expression.
Clinical and pathological characteristics nº Cases(%)
nº miR-31
High 1 (%)
nº miR-31
Low 2 (%) p
miR-31 3 pre CRT 78 (100%) 27 (34.2) 51 (65.8)
0.267
Age <60 24 (30.7) 10 (41.6) 14 (58,4)
>60 54 (69.3) 17 (31.4) 37 (68.6)
Sex
Male 47 (60) 15 (31.9) 32 (68.1)
0.454Female 31 (40) 8 (68.1) 19 (31.9)
ECOG 4
0 49 (62.8) 14 (28.5) 35 (71.5)
0.113I 29 (37.2) 13 (71.5) 16 (28.5)
Clinical stage pre CRT 5
II 4 (5.2) 3 (75) 1 (25)
0.121III 73 (94.8) 24 (30.7) 49 (69.3)
Neoadjuvant CRT RT + 5-FU 6 based 78 (100%)
Adjuvant therapy
5-FU 55 (70.5) 20 (36.4) 35 (63.6)
0.407FOLFOX 7 6 (7.7) 3 (50) 3 (50)
Other 17 (21.8) 4 (23.5) 13 (76.5)
Grade pre CRT
Low 20 (25.8) 5 (25) 15 (75)
0.410High 50 (64) 20 (40) 30 (60)
ND 8 8 (10.2) 2 (25) 6 (75)
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Table 1. Cont.
Clinical and pathological characteristics nº Cases(%)
nº miR-31
High 1 (%)
nº miR-31
Low 2 (%) p
ypT 9
ypT0 10 (12.8) 1 (10) 9 (90)
0.372
ypT1-2 33 (42.4) 13 (39.4) 20 (60.6)
ypT3-4 32 (41) 12 (37.5) 20 (62.5)
ypTx 3 (3.8) 1 (33.3) 2 (66.7)
ypN 10
pN0 61 (78.2) 18 (29.5) 43 (70.5)
0.086pN+ 17 (21.8) 9 (52.9) 8 (47.1)
Pathological stage
ypT0N0 10 (12.8) 1 (10) 9 (90)
0.133
ypI 30 (38.5) 11 (36.6) 19 (63.4)
ypII 21 (27) 6 (28.6) 15 (71.4)
ypIII 17 (21.7) 9 (52.9) 8 (47.1)
Downstaging No 19 (24.3) 9 (47.4) 10 (52.6) 0.143Yes 59 (75.7) 18 (52.6) 41 (47.4)
Pathology response
Complete response 10 (12.8) 1 (10) 9 (90)
0.018
Moderate response 30 (38.5) 7 (23.3) 23 (76.7)
Minimal response 15 (19.2) 5 (33.3) 10 (66.7)
Poor response 23 (29.5) 14 (60.8) 9 (39.2)
1 miR-31 high = ∆CT miR-31 < 0.34 (cut-off established by a receiver operating characteristic (ROC) curve);
2 miR-31 low = ∆CT miR-31 > 0.34 (cut-off established using a ROC curve); 3 miR-31 = microRNA 31;
4 ECOG = Eastern Cooperative Oncology Group; 5 CRT = Chemoradiotherapy; 6 5-FU = 5-fluorouracil;
7 FOLFOX = Fluorouracil, Oxaliplatin, Leucovorin; 8 ND = No data; 9 ypT = tumor size after CRT;
10 ypN = pathological lymph node after CRT.
2.2. miR-31 Deregulation Predicts Pathological Response to Neoadjuvant Chemoradiotherapy (CRT) in
LARC Patients
Receiver operating characteristic (ROC) curves were generated in order to investigate the potential
utility of miR-31 as a predictive biomarker of response to neoadjuvant CRT. miR-31 expression
levels provide an area under the curve (AUC) value of 0.71 (95% confidence interval (CI) = 0.57 to
0.84; p = 0.001) with 60.8% sensitivity and 76.3% specificity in distinguishing rectal cancer from poor
responders to minimal, moderate, and complete responders. Negative predictive value (NPV) was
82.3% and positive predictive value (PPV) was 51.8% (Figure 2 and Table 2).
1 
 
 Figure 2. Receiver operating characteristic (ROC) Curve. Based on this ROC curve, the cutoff point
that provides the best sensitivity and specificity to separate rectal cancer from any response to absence
of response (Ryan 3) was selected. According with this criteria, miR-31 high (or overexpressed) was
defined as ∆CT miR-31 < 0.34 and miR-31 low was defined as ∆CT miR-31 > 0.34. The dash line
represents the coordinated points of the ROC curve. The solid line represents the ROC curve diagonal
reference line.
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Table 2. MiR-31 predicts pathological response to neoadjuvant CRT.
Responders vs. Non-Responders
Response Response 1 Non-Response 2 Total
miR-31 high 3 13 14 27
miR-31 low 4 42 9 51
Total 55 23 78
NPV 5 (%) 82.3 Specificity (%) 76.3
PPV 6 (%) 51.8 Sensitivity (%) 60.8
1 “Response” = moderate, minimal, or complete response; 2 “Non-Response” = poor pathological response;
3 miR-31 high = ∆CT miR-31 < 0.34 (cutoff derived by receive operating characteristic curve); 4 miR-31 low= ∆CT
miR-31 > 0.34 (cutoff derived by receive operating characteristic curve); 5 NPV = negative predictive value;
6 PPV = positive predictive value.
Moreover, multivariable logistic regression analyses revealed that miR-31 expression levels
measured before the beginning of neoadjuvant CRT is a predictive pathological response marker.
The odds ratio for non-responders was 0.18 (95% CI = 0.06 to 0.57; p = 0.003) (Table 3).
Table 3. Multivariable logistic analysis for miR-31 expression measured pre neoadjuvant CRT
and the rest of clinic-pathological factors measured before neoadjuvant CRT in responder and
non-responder patients.
Responders 1 vs. Non-Responders 2 3 OR (95% CI 4) p
Age, <60 vs. >60 0.97 (0.30 to 3.06) 0.962
Gender, Female vs. Male 1.25 (0.41 to 3.86) 0.452
ECOG 5, O vs. I 0.79 (0.25 to 2.51) 0.799
Grade pre CRT 6, high-moderate vs. low 1.25 (0.53 to 2.96) 0.600
Clinical stage, II vs. III 2.51 (0.20 to 30.37) 0.468
miR-31 high 7 vs. low 8 0.18 (0.06 to 0.57) 0.003
1 “Response” = moderate, minimal or complete response; 2 “Non-Response” = poor pathological response;
3 OR = Odds ratio; 4 CI = Confidence interval; 5 ECOG = Eastern Cooperative Oncology Group;
6 CRT = chemoradiotherapy; 7 miR-31 high = ∆CT miR-31 < 0.34 (cutoff derived by receive operating characteristic
curve); 8 miR-31 low= ∆CT miR-31 > 0.34 (cutoff obtained by a receive operating characteristic curve).
2.3. High miR-31 Levels Determines Poor Outcome in LARC Patients Treated with Neoadjuvant CRT
To further evaluate the clinical significance of miR-31 in LARC, we next investigated whether
miR-31 levels could serve as a predictor of patient outcome. Interestingly, patients with higher
miR-31 levels had statistically significantly worse overall survival (p = 0.008, Figure 3A). Despite high
miR-31 expression also associated with shorter disease-free survival, significance was not achieved
(p = 0.070)—probably due to the small number of cases included in this cohort (Figure 3B).
Additionally, Cox proportional hazard regression analyses showed that in the univariate analysis,
poor outcome in LARC patients was related to high levels of miR-31 (Hazard Ratio (HR) = 5.077;
95% CI = 1.366 to 18.863; p = 0.015) and pathological stage (HR = 1.890; 95% CI = 1.027 to 3.478;
p = 0.043). In the same way, multivariable analysis proved that high levels of miR-31 can be used
as an independent prognostic biomarker for determining outcome in LARC patients treated with
neoadjuvant CRT (HR = 0.206; 95% CI = 0.051 to 0.840; p = 0.028) (Table 4).
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Table 4. LARC patients factors predictive of poor overall survival: Univariate and multivariable analyses.
Variables
Univariate Multivariate
HR 1 (95% CI 2) p HR (95% CI) p
Age, >60 vs. <60 0.915 (0.246 to 3.407) 0.895
Sex, female vs. male 1.024 (0.56 to 1.86) 0.928
linical stage, II vs. III 2.229 (0.274 to 18.132) 0.453
Pathological ypT 3, ypT0 vs.
ypT1/T2 vs. ypT3/ 4
2.064 (0.214 to 19.902) 0.531
Pathological ypN 4, N+ vs. N´ 2.907 (0.918 to 9.211) 0.070
Pathological stage 1.890 (1.027 to 3.478) 0.043 2.411 (1.136 to 5.114) 0.022
Pathological response, poor vs.
complete vs. moderate vs. minimal 1.346 (0.70 to 2.56) 0.366
MiR-31 expression, high 5
(∆CT < 0.34) vs. low 6 (∆CT > 0.34)
5.077 (1.366 to 18.863) 0.015 0.206 (0.051 to 0.840) 0.028
1 HR = Hazard ratio; 2 CI = Confidence Interval; 3 ypT = tumor size after CRT; 4 ypN = pathological lymph
node after CRT; 5 miR-31 high = ∆CT m R-31 < 0.34 (cutoff derived by receive operating cha a teristic curve);
6 miR-31 low = ∆CT miR-31 > 0.34 (cutoff derived by receive operating characteristic curve).
3. Discussion
Personalized treatment selection for patients with LARC relies on clinical variables measured
prior to neoadjuvant CRT. Taken into account that, depending on the series, between 45% and
20% of the patients do not respond to neoadjuvant CRT therapy, and the lack of any clinical and
pathological factors to guide the initial treatment, novel predictive biomarkers are needed to avoid
toxicity and surgery delays. In this context, prior studies have reported the potential usefulness of
some gene signatures and microRNA expression profiles to predict neoadjuvant CRT response [14,17].
However, those biomarkers are not well validated for use in daily clinical practice. Here, we show that
miR-31 expression levels measured before starting any treatment have the potential ability to predict
pathological response, overall survival, and progression-free survival in patients with LARC treated
with 5-FU based neoadjuvant CRT.
We decided to evaluate the potential clinical value of miR-31 in predicting CRT response due to
the previously-reported oncogenic role of this microRNA in CRC [23]. We found a similar prevalence
(around 34%) of miR-31 overexpression to what has been previously reported in the literature (between
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10% and 38% depending on the cohort and the stage of the disease) [23,24]. In concordance with our
findings, it has been reported that miR-31 suppression increments sensitivity to 5-FU at the initial
stage, and also affects invasion and cell migration in HCT-116 cells [22]. Moreover, several studies
have reported the potential value of microRNAs to predict neoadjuvant CRT response; however, these
works did not evaluate miR-31 expression levels [25,26].
In our study, high miR-31 levels were significantly associated with the lack of pathological
response and patients with low miR-31 expression tended to have better response. As indicated
above, the pathological response can be predicted with a specificity of 76.3%. Prior works pointed
out that the degree of tumor regression might be a very important clinical tool, as it could be used as
a prognostic marker; however, the clinical significance of tumor pathological response is still under
investigation [7,27]. In our cohort, pathological response is not associated with overall survival (OS)
and disease-free survival (DFS). However, we showed that miR-31 deregulation is able to predict
pathological response, DFS, and OS. In this way, 78% of the patients with high miR-31 expression were
alive at 6 years follow up compared with 96% of those with low miR-31. In addition, 65% of the patients
with high miR-31 had a recurrence within the first three years of follow up, compared with 86% of
the patients with low miR-31. Those results suggest the strength of miR-31 as a predictive biomarker
to guide multidisciplinary treatment in patients with LARC, since cases with high miR-31 had no
appreciable clinical benefit from neoadjuvant CRT. Considering these results, high miR-31 patients
could benefit from an alternative therapeutic approach, different than 5-FU-based neoadjuvant CRT.
Measuring miR-31 expression levels as a predictive biomarker for neoadjuvant CRT in LARC
has the advantage that is easily detected from small amounts of routinely-prepared formalin-fixed
paraffin-embedded (FFPE) endoscopic samples by using a RT-PCR. Furthermore, microRNAs have
the ability to continue stable, even when subjected to extreme conditions such as very low or high
pH levels, boiling, longer storage time, and multiple freeze-thaw cycles [28]. Limitations of our study
include the low number of cases included, the lack of validation in an independent larger cohort, and
that it was a retrospective study instead of a prospective one. Therefore, the conclusions provided by
this study have to be interpreted with caution and the potential clinical usefulness of miR-31 has to be
further confirmed in forthcoming studies and controlled randomized clinical trials before a potential
inclusion in clinical protocols. However, it is also true that this study is larger than other studies
evaluating neoadjuvant CRT treatments, and the treatment regimen was very homogeneous.
Finally, prior works have described the interaction of miR-31 with important tumor suppressor
genes, such as the enhancer of zeste homolog 2 (EZH2) [29] and the hypoxia-inducible transcription
factor 1α (HIF-1α) [30]. In the same way, in other tumor models, miR-31 represses the regulatory
subunit B alpha isoform of the tumor suppressor PP2A (PPP2R2A) [31]. We previously reported that
this subunit downregulation is a common event in colorectal cancer patients and its relation with
the resistance to 5-FU [32]. According to this and despite there are likely to be multiple explanations
for primary or acquired resistance to neoadjuvant CRT—exploring the role and interaction of miR-31
and PPP2R2A to predict neoadjuvant CRT response in LARC patients could be of great interest for
future research.
4. Materials and Methods
4.1. Patient Selection
Eighty-one patients diagnosed with LARC and treated with neoadjuvant CRT between the
beginning of 2007 and the end of 2012 (6 years) at the University Hospital Fundación Jiménez Díaz,
(Madrid, Spain) were retrospectively selected and included in this study. They were followed-up until
February 2016.
All patients had a preoperative staging based on transrectal ultrasound (TRUS) and/or magnetic
resonance image (MRI) of the pelvis. In addition, a full body computed tomography scan (FBCT) was
performed to exclude stage IV disease. The patients were treated with rule-based chemoradiotherapy
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regimens based on 5-FU and underwent surgery after one and a half to two months after neoadjuvant
CRT completion. Every patient gave written informed consent for tissue storage and analysis at
Fundación Jiménez Díaz biobank, Madrid (Spain). Fundación Jiménez Díaz University Hospital,
Madrid (Spain) institutional review board approved the study.
4.2. Pathologic Response and Tumor Samples
The Fundación Jimenez Diaz biobank provided the tumor samples. All tissue derived from the
surgical resection were classified in concordance with the College of American Pathologist guidelines
for invasive carcinomas (TNM, 7th ed.). Two independent pathologists blinded to all patients’ clinical
data evaluated tumor regression grade according to the modified Ryan classification that categorizes
tumors in four levels of response: complete, moderate, minimal, and poor response. Complete
response score 0 indicates no viable cancer cells; moderate score 1 indicates single cells or little groups
of cancer cells; minimal score 2 indicates residual cancer outgrown by fibrosis; and poor response
scores 3 indicates minimal or no tumor kill with extensive residual cancer. Every regression grade was
compared with the primary tumor, in concordance with clinical guidelines [33].
4.3. RNA Isolation
We isolated total RNA from formalin-fixed paraffin-embedded (FFPE) tumor biopsies, applying
RecoverAll Total Nucleic Acid Isolation kit Ambion (Thermo Fisher Scientific, USA in accordance
with manufacturer’s instructions. We eluted total RNA and quantified it with a NanoDrop
Spectrophotometer (Thermo scientific, Waltham, MA, USA)
4.4. Quantification of MicroRNA Expression Levels
Samples were reverse transcribed using the TaqManHMicroRNA Reverse Transcription Kit
(Applied Biosystems Waltham, MA, USA). Working with TaqMan MicroRNA Assays (Applied
Biosystems, USA) specific for miR-31 (reference number: 002279) and U6B as internal control, mature
miRNAs were quantified by quantitative real-time reverse transcription polymerase chain reaction
(RT-PCR). TaqMan MicroRNA assays have an ultra-high sensitivity and can detect as few as ten copies
of the target transcript in a sample and also have a dynamic range greater than seven logs. Reactions
were carried out using an Applied Biosystems 7500 Sequence Detection System. Conditions: 95 ˝C for
10 min, followed by 45 cycles of 95 ˝C for 15 s, and 60 ˝C for 1 min. The ∆CT method was performed
to analyze relative gene expression data.
4.5. Statistical Analysis
We used SPSS v14.0 (SPSS Inc, Chicago, IL, USA) for statistical analyses. We applied the χ2
test (Fisher exact test) based on bimodal distribution of data to evaluate the correlation between
miR-31 overexpression and the clinical and pathological variables. All reported p values are two-sided.
We made a receiver operating characteristic (ROC) curve to establish a cutoff for miR-31 expression,
calculated its 95% confidence interval, and selected the cutoff point that provides us with the best
specificity and sensitivity to differentiate rectal cancer pathological response, in order to assess the
potential usefulness of miR-31 as a predictive biomarker. According to this criteria, we considered
up-regulation when miR-31 expression levels (∆CT) were lower than 0.34. We defined DFS as the
time from surgery until recurrence, appearance of a secondary tumor, or death, and OS as the time
from the date of diagnosis to the date of last follow-up or death, and applied the Kaplan-Meier
method and survival comparisons with the log-rank test and Breslow. Then, we adjusted the Cox
proportional hazards model by taking into consideration significant parameters in univariate analysis
and considered a p value <0.05 statistically significant. We followed the Reporting Recommendations
for Tumor Marker Prognostic Studies (REMARK) guideline [34].
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5. Conclusions
In conclusion, our work shows evidence for the potential utility of miR-31 as a predictive
biomarker for pathological response and outcome in patients with LARC treated with neoadjuvant
CRT—a concept that can be very interesting to better select treatment options in patients with LARC
and that can be incorporated into daily clinical practice. However, more studies are needed to better
define the biological and clinical significance of miR-31 in rectal cancer. Furthermore, a validation of
these results in a larger independent LARC patient cohort is necessary to validate our results.
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MiR-31 MicroRNA-31
FFPE formalin-fixed paraffin-embedded
5-FU 5-fluorouracil
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anti-EGFR anti-epithelial growth factor receptor
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